The Company’s growth strategy is primarily driven by the development of its orphan oncology candidates which meet an established and unaddressed therapeutic need for a relatively limited population of patients, and products with very high sales potential – benefiting from more favorable price and reimbursement policies.
Onxeo’s orphan oncology products are:
Livatag® (doxorubicin Transdrug™): in Phase III in the treatment of primary liver cancer
Beleodaq® (belinostat): registered in the U.S. in relapsed or refractory peripheral T-cell lymphoma (PTCL).
AsiDNA™: The first-in-class siDNA (signal-interfering DNA) which has successfully undergone a proof-of-concept Phase I trial in metastatic melanoma.
Validive® (clonidine Lauriad®): finalized positive results of Phase II in the treatment and prevention of radio/chemotherapy induced severe oral mucositis in patients suffering from head and neck cancer. The company is seeking for a partner to further co-develop Validive®.
In the medium to long term, the Company could market directly these high value-added products with a strong profitability profile in order to benefit from the full profit margin generated.
Furthermore, Onxeo has successfully developed and registered two non-strategic drugs in Europe and the United States, demonstrating its teams’ expertise and know-how.
These products are based on Onxeo’s innovative proprietary technology Lauriad® that makes it possible to improve the efficacy and tolerance profile of an active ingredient for the chosen indication: Loramyc®/Oravig® , indicated for the treatment of oropharyngeal candidiasis, and Sitavig®/Labiriad®, indicated for the treatment of recurrent herpes labialis. With a strong market potential, these products are dedicated to be marketed by international partners, mainly via licensing agreements, contributing towards the funding of development projects.